Devices and formulations for pulmonary vaccination

Wouter F. Tonnis*, Anne J. Lexmond, Henderik W. Frijlink, Anne H. De Boer, Wouter L.J. Hinrichs

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: Book/Film/Article reviewProfessional

34 Citaten (Scopus)


Introduction: Pulmonary vaccination could be a promising alternative to vaccination by injection. Administration of a vaccine to the lungs does not require the use of needles, which reduces the number of trained healthcare workers needed, the risk of needle-stick injuries and needle waste. Besides a systemic immune response, pulmonary vaccination may also induce a mucosal immune response. Such a local response may increase the effectiveness of vaccination against airborne pathogens. Although this route of administration has been studied for decades, no pulmonary vaccine is commercially available yet, due to various challenges mostly intrinsic to pulmonary drug delivery and vaccine formulation. Areas covered: This review discusses the inhalation devices and formulation strategies that may be suitable for the pulmonary administration of vaccines. In addition, critical parameters are addressed, such as the target population, to help assessing whether pulmonary administration of a specific vaccine may be feasible and beneficial or not. Expert opinion: A combined approach of inhalation device and vaccine formulation development is essential. This should result in a system that can effectively be used by the target population and can be produced at low costs. Only then, this challenging administration route can be successfully applied to large-scale vaccination programs. © 2013 Informa UK, Ltd.
Originele taal-2English
Pagina's (van-tot)1383-1397
Aantal pagina's15
TijdschriftExpert Opinion on Drug Delivery
Nummer van het tijdschrift10
StatusPublished - okt-2013

Citeer dit